David Weinstein, Ph.D., Acting President & Chief Technology Officer
Dr. Weinstein has over 10 years of experience in software development, image processing, and managing the development of software systems for medical imaging.
Prior to the acquisition by Numira, he was the President and Chief Technology Officer for Visual Influence, Inc., a company formed in 2001 to focus primarily on exporting technology from the University of Utahâ€™s Scientific Computing and Imaging Institute to commercial applications.Â As the President and CTO of Visual Influence, Dr. Weinstein set the overall direction for the company, sought out and fostered new project opportunities, managed project development for all Visual Influence contracts, and directed day-to-day operations.
Dr. Weinstein is also a technical manager for the NIH NCRR Center for Integrative Biomedical Computing, within the Scientific Computing and Imaging Institute at the University of Utah. As a Technical Manager, Dr. Weinstein assists in defining and communicating the Centerâ€™s direction, develops collaborative research projects, and coordinates the Centerâ€™s software development efforts to meet the needs of the biomedical community.
Dr. Weinstein received his Ph.D. in computer science from the University of Utah and B.S. degrees in computer science and mathematics from U.C. Berkeley.
Daniel Small, Ph.D., Vice President, Scientific & Business Development
Dr. Small has 19 years of experience in preclinical drug development with more than 60 publications including seven book chapters in the area of neuroscience.
Prior to the acquisition by Numira, he was Sr. Director of Bothell Operations for Ricerca Biosciences (formerly MDS Pharma Services), a preclinical global CRO with more than 1,300 assays and models from medicinal chemistry to toxicology. He was responsible for two 40,000 sf facilities including a GLP vivarium, a histology lab and a robotics lab. He was responsible for all aspects of the operation, including P&L, quality assurance, facilities, technical sales, and health and safety.
Prior to joining MDS Pharma Services he spent five years as a senior manager at Lexicon Pharmaceuticals, Texas. There, Dr. Small participated in screening more than 3000 unique transgenic mouse lines using behavioral and biological assays focusing on the therapeutic areas of pain, schizophrenia, anxiety, depression, neurodegeneration, neurogenesis, and cognition. Prior to joining Lexicon Pharmaceuticals, he was an Adjunct Professor at the University of Ottawa, and Research Officer at the National Research Council of Canada where he ran a stroke research lab.
Dr. Small received his Ph.D. in biology and M.Sc. in physiology from the University of Ottawa and his B.Sc. in zoology from the University of Toronto.
Christopher Jerome, B.Vet.Med., Ph.D., Technical Director
Dr. Jerome has 30 years of biomedical research experience and over 60 publications, primarily in the area of animal models of skeletal diseases.
His professional experience includes 5 years as a consultant with Think Bone Consulting, 8 years as a cofounder and executive of SkeleTech, a CRO specializing in bone and CNS models, 12 years is academia at Wake Forest University School of Medicine, and 3 years in osteoporosis research with Sandoz in Switzerland.
Chris received his veterinary degree from the Royal Veterinary College, London, and a Ph.D. in Comparative Pathology from U.C. Davis.